RR (95% CI) | Osteoporosis | Reduced BMD | |||||
Spine L2–4 | Total hip | Spine L2–4 | Total hip | ||||
Male gender | 2.54 (0.88 to 6.16) | 2.05 (0.73 to 4.56) | 1.80 (1.23 to 2.41) | 1.43 (0.74 to 2.47) | |||
Postmenopausal status | 1.93 (1.17 to 3.07) | 1.60 (0.78 to 3.85) | 2.05 (0.99 to 4.55) | 1.45 (0.66 to 3.15) | |||
BMI, kg/m2 | 0.90 (0.84 to 0.96) | 0.74 (0.58 to 0.90) | 0.99 (0.94 to 1.04) | 0.92 (0.87 to 0.97) | |||
Familial osteoporosis | 1.54 (0.93 to 2.02) | 1.15 (0.44 to 3.20) | 2.16 (1.23 to 3.39) | 2.47 (1.30 to 4.00) | |||
Symptom duration, weeks | 1.001 (0.99 to 1.00) | 1.004 (1.00 to 1.01) | 1.001 (0.99 to 1.00) | 1.002 (1.00 to 1.00) | |||
Positive RF | 1.17 (0.87 to 1.38) | 1.24 (0.64 to 2.48) | 1.31 (1.09 to 1.45) | 1.07 (0.83 to 1.43) |
BMD, bone mineral density; BMI, body mass index; RF, rheumatoid factor; RR, relative risk.
All variables were adjusted for age, gender, menopausal status, race, smoking and alcohol status, except for themselves.
Symptom duration, rheumatoid factor status, Disease Activity Score, Health Assessment Questionnaire and total Sharp–van der Heijde score were additionally adjusted for each other.